Jim Simons’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-278,400
| Closed | -$108K | – | 3938 |
|
|
2020
Q1 | $108K | Buy |
278,400
+37,686
| +16% | +$13.6K | ﹤0.01% | 3214 |
|
|
2019
Q4 | $99K | Sell |
240,714
-288,261
| -54% | -$479K | ﹤0.01% | 3328 |
|
|
2019
Q3 | $1.06M | Sell |
528,975
-38,673
| -7% | -$78.3K | ﹤0.01% | 2570 |
|
|
2019
Q2 | $1.23M | Sell |
567,648
-53,300
| -9% | -$136K | ﹤0.01% | 2596 |
|
|
2019
Q1 | $1.96M | Sell |
620,948
-97,100
| -14% | -$314K | ﹤0.01% | 2313 |
|
|
2018
Q4 | $1.79M | Sell |
718,048
-21,200
| -3% | -$70.6K | ﹤0.01% | 2291 |
|
|
2018
Q3 | $2.97M | Buy |
739,248
+133,825
| +22% | +$590K | ﹤0.01% | 2085 |
|
|
2018
Q2 | $2.29M | Buy |
605,423
+76,510
| +14% | +$200K | ﹤0.01% | 2200 |
|
|
2018
Q1 | $1.23M | Buy |
528,913
+42,300
| +9% | +$66.9K | ﹤0.01% | 2573 |
|
|
2017
Q4 | $754K | Buy |
486,613
+75,200
| +18% | +$121K | ﹤0.01% | 2771 |
|
|
2017
Q3 | $876K | Buy |
411,413
+60,700
| +17% | +$207K | ﹤0.01% | 2615 |
|
|
2017
Q2 | $1.58M | Buy |
350,713
+97,300
| +38% | +$353K | ﹤0.01% | 2380 |
|
|
2017
Q1 | $763K | Buy |
253,413
+38,400
| +18% | +$113K | ﹤0.01% | 2635 |
|
|
2016
Q4 | $593K | Buy |
215,013
+52,400
| +32% | +$150K | ﹤0.01% | 2721 |
|
|
2016
Q3 | $509K | Buy |
162,613
+72,400
| +80% | +$264K | ﹤0.01% | 2811 |
|
|
2016
Q2 | $462K | Buy |
90,213
+24,900
| +38% | +$120K | ﹤0.01% | 2821 |
|
|
2016
Q1 | $267K | Buy |
65,313
+3,100
| +5% | +$16.6K | ﹤0.01% | 3009 |
|
|
2015
Q4 | $505K | Sell |
62,213
-4,400
| -7% | -$36.7K | ﹤0.01% | 2735 |
|
|
2015
Q3 | $562K | Sell |
66,613
-25,034
| -27% | -$231K | ﹤0.01% | 2587 |
|
|
2015
Q2 | $862K | Sell |
91,647
-5,466
| -6% | -$50.9K | ﹤0.01% | 2525 |
|
|
2015
Q1 | $899K | Buy |
97,113
+20,000
| +26% | +$192K | ﹤0.01% | 2363 |
|
|
2014
Q4 | $713K | Sell |
77,113
-7,000
| -8% | -$58.9K | ﹤0.01% | 2306 |
|
|
2014
Q3 | $751K | Sell |
84,113
-59,185
| -41% | -$431K | ﹤0.01% | 2167 |
|
|
2014
Q2 | $1.13M | Sell |
143,298
-77,315
| -35% | -$584K | ﹤0.01% | 2005 |
|
|
2014
Q1 | $1.75M | Buy |
220,613
+1,700
| +0.8% | +$13.7K | ﹤0.01% | 1841 |
|
|
2013
Q4 | $1.36M | Buy |
218,913
+8,800
| +4% | +$46.1K | ﹤0.01% | 1933 |
|
|
2013
Q3 | $744K | Buy |
210,113
+10,300
| +5% | +$23.4K | ﹤0.01% | 2140 |
|
|
2013
Q2 | $390K | Buy |
+199,813
| New | +$401K | ﹤0.01% | 2325 |
|
Jim Simons's CORV Position: Q2 2020 in Review
Jim Simons sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q2 2020, closing a stake of 278,400 shares — an estimated $108K sold.
Jim Simons first reported a position in CORV in Q2 2013 and held it in 28 quarters. The position peaked at $2.97M in Q3 2018. 0 funds tracked by Wall St. Rank hold CORV as of Q2 2020.
- Jim Simons reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q2 2020 after selling out during the quarter.
- Jim Simons sold 278,400 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q2 2020, an estimated $108K.
- Jim Simons first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q2 2013 and held it in 28 quarters.
- Jim Simons's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $2.97M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q2 2020.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.